title: Diverse effects of long-term treatment with imidapril and irbesartan on cell growth signal, apoptosis and collagen type I expression in the left ventricle of spontaneously hypertensive rats.
abstract: To compare diverse effects of angiotensin II type 1 receptor antagonists (irbesartan) and angiotensin converting enzyme inhibitors (imidapril) on left ventricular remodeling in spontaneously hypertensive rats (SHR). Thirty male SHR were randomly divided into three groups: SHR-IR (treated with irbesartan, 50 mg/kg), SHR-IM (imidapril, 3 mg/kg), SHR-C (placebo). Ten male Wistar Kyoto rats (WKY) treated with placebo acted as the control. All treatments were administered once daily from 14 to 27 weeks of age. Imidapril and irbesartan have the similar inhibitor effects on blood pressure and left ventricular mass indexes in SHR. Despite both drugs suppressed ERK-1 protein expression, decreased cardiomyocytes apoptosis index, blocked collagen type I deposition, reduced TGF-beta(1) gene expression in SHR, imidapril elicits a stronger inhibitory effect. Irbesartan had little effect on MKP-1 protein expression, but imidapril decreased it significantly. As a result, the ERK-1/MKP-1 ratio in SHR-IR was significantly greater than that in SHR-IM (P < 0.05). These results suggest that the balance between MKP-1 and ERKs in myocardial tissue is important for cardiac cell proliferation and growth. They also indicate that the similar efficacy of antihypertensive treatment in reducing blood pressure does not predict the similar capacity to control the individual facet of left ventricular remodeling. Irbesartan is more effective in regressing the homeostasis between ERK-1 and MKP-1, however imidapril is superior in suppressing apoptosis and collagen synthesis in cardiac tissue.
authors.affiliation: Department of Cardiology, Renmin Hospital, Wuhan University School of Medicine, Wuhan 430060, People's Republic of China.
authors.forename: Jin-Ming
authors.initials: JM
authors.lastname: Wang
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Zhong-Sheng
authors.initials: ZS
authors.lastname: Zhu
authors.forename: Mei-Chun
authors.initials: MC
authors.lastname: Zhang
authors.forename: Yi
authors.initials: Y
authors.lastname: Zou
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Li
authors.forename: Ming-Jiang
authors.initials: MJ
authors.lastname: Li
authors.forename: Xue-Jun
authors.initials: XJ
authors.lastname: Jiang
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Li
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D018797:Cell Cycle Proteins; D024042:Collagen Type I / Q000096:biosynthesis*; D054638:Dual Specificity Phosphatase 1; D015870:Gene Expression / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D006973:Hypertension / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D048289:Imidazolidines; D017874:Immediate-Early Proteins / Q000096:biosynthesis; D000077405:Irbesartan; D008297:Male; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000096:biosynthesis; D010749:Phosphoprotein Phosphatases; D054645:Protein Phosphatase 1; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases / Q000096:biosynthesis; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D015398:Signal Transduction / Q000187:drug effects*; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000096:biosynthesis; D053773:Transforming Growth Factor beta1
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D018797:Cell Cycle Proteins; D024042:Collagen Type I; D007093:Imidazoles; D048289:Imidazolidines; D017874:Immediate-Early Proteins; D013777:Tetrazoles; C508962:Tgfb1 protein, rat; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; C065166:imidapril; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases; D010749:Phosphoprotein Phosphatases; D054645:Protein Phosphatase 1; D054638:Dual Specificity Phosphatase 1; C517021:Dusp1 protein, rat; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases; D000077405:Irbesartan